StockCIK 2058707
Attovia Therapeutics, Inc. (ATTO): Insider Trades and Fund Holdings
In the past 12 months, Attovia Therapeutics, Inc. insiders reported 4 open-market purchases worth $20.6M and 2 sales worth $4.50M; 0 of the sales were reported as made under a 10b5-1 trading plan.
4Insider buys, 12 months
$20.6MBought by insiders, 12 months
$4.50MSold by insiders, 12 months
0Tracked funds holding
Timeline: news and trades
Company filings (8-K), insider trades, notices of planned sales (Form 144) and fund moves in the past year, newest first.
- Aug 6, 2026Insider buyOther Goldman Sachs Group Inc bought $8.5 million
- Aug 6, 2026Insider buyDirector Colin Walsh bought $8.5 million
- Aug 5, 2026Insider saleOther Goldman Sachs Group Inc sold $2.3 million
- Aug 5, 2026Insider saleDirector Colin Walsh sold $2.3 million
- Aug 5, 2026Insider buyOther Goldman Sachs Group Inc bought $1.8 million
- Aug 5, 2026Insider buyDirector Colin Walsh bought $1.8 million
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Aug 13, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 13 | Goldman Sachs Group IncOther | ▲ BUY | $8.50M |
| Aug 13 | Colin WalshDirector | ▲ BUY | $8.50M |
| Aug 13 | Goldman Sachs Group IncOther | ▼ SELL | $2.25M |
| Aug 13 | Colin WalshDirector | ▼ SELL | $2.25M |
| Aug 13 | Goldman Sachs Group IncOther | ▲ BUY | $1.78M |
| Aug 13 | Colin WalshDirector | ▲ BUY | $1.78M |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Goldman Sachs Group Inc | Other | 2 | $10.3M | 1 | $2.25M |
| Colin Walsh | Director | 2 | $10.3M | 1 | $2.25M |
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →